

Takis Athanasopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8435723/publications.pdf>

Version: 2024-02-01

34
papers

1,313
citations

430874

18
h-index

414414

32
g-index

34
all docs

34
docs citations

34
times ranked

2136
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. <i>Nature Communications</i> , 2017, 8, 16105.	12.8	175
2	Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19940-19945.	7.1	136
3	Codon and mRNA Sequence Optimization of Microdystrophin Transgenes Improves Expression and Physiological Outcome in Dystrophic mdx Mice Following AAV2/8 Gene Transfer. <i>Molecular Therapy</i> , 2008, 16, 1825-1832.	8.2	107
4	β-catenin as a potential key target for tumor suppression. <i>International Journal of Cancer</i> , 2011, 129, 1541-1551.	5.1	93
5	Langerin negative dendritic cells promote potent CD8 ⁺ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3041-3046.	7.1	82
6	Cell-derived Apolipoprotein E (ApoE) Particles Inhibit Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 46011-46016.	3.4	81
7	Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice. <i>Human Gene Therapy</i> , 2014, 25, 98-108.	2.7	80
8	Abnormal splicing switch of DMD's penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. <i>Nature Communications</i> , 2015, 6, 7205.	12.8	76
9	Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic dog. <i>Journal of Gene Medicine</i> , 2011, 13, 497-506.	2.8	57
10	Delivery of AAV2/9-Microdystrophin Genes Incorporating Helix 1 of the Coiled-Coil Motif in the C-Terminal Domain of Dystrophin Improves Muscle Pathology and Restores the Level of ±1-Syntrophin and ±Dystrobrevin in Skeletal Muscles of mdx Mice. <i>Human Gene Therapy</i> , 2011, 22, 1379-1388.	2.7	52
11	Gene therapy for muscular dystrophy: current progress and future prospects. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 849-866.	3.1	44
12	RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. <i>Human Molecular Genetics</i> , 2008, 17, 2622-2632.	2.9	40
13	Genome-wide Computational Analysis Reveals Cardiomyocyte-specific Transcriptional Cis-regulatory Motifs That Enable Efficient Cardiac Gene Therapy. <i>Molecular Therapy</i> , 2015, 23, 43-52.	8.2	36
14	Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. <i>Gene Therapy</i> , 2002, 9, 21-29.	4.5	29
15	Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells Into Skeletal Myocytes. <i>Molecular Therapy</i> , 2011, 19, 1331-1341.	8.2	29
16	Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization. <i>BMC Genomics</i> , 2010, 11, 345.	2.8	26
17	piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. <i>Nucleic Acids Research</i> , 2016, 44, 744-760.	14.5	25
18	Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice. <i>Human Molecular Genetics</i> , 2000, 9, 2545-2551.	2.9	23

#	ARTICLE	IF	CITATIONS
19	The Landscape of Early Clinical Gene Therapies outside of Oncology. <i>Molecular Therapy</i> , 2019, 27, 1706-1717.	8.2	18
20	Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD). <i>Current Gene Therapy</i> , 2015, 15, 395-415.	2.0	17
21	Codon Optimization of the Microdystrophin Gene for Duchenne Muscular Dystrophy Gene Therapy. <i>Methods in Molecular Biology</i> , 2011, 709, 21-37.	0.9	16
22	Human Apolipoprotein E Expression from Mouse Skeletal Muscle by Electrotransfer of Nonviral DNA (Plasmid) and Pseudotyped Recombinant Adeno-Associated Virus (AAV2/7). <i>Human Gene Therapy</i> , 2008, 19, 569-578.	2.7	14
23	Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice. <i>Atherosclerosis</i> , 2009, 204, 121-126.	0.8	13
24	Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer. <i>Journal of Controlled Release</i> , 2012, 159, 376-383.	9.9	9
25	Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates. <i>Gene Therapy</i> , 2001, 8, 1580-1586.	4.5	7
26	Fusion of Ubiquitin to HIV Gag Impairs Human Monocyte-Derived Dendritic Cell Maturation and Reduces Ability to Induce Gag T Cell Responses. <i>PLoS ONE</i> , 2014, 9, e88327.	2.5	6
27	Activity of different vaccine-associated promoter elements in human dendritic cells. <i>Immunology Letters</i> , 2008, 115, 117-125.	2.5	5
28	Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 491-498.	3.4	5
29	Fragmentation of SIV-gag Vaccine Induces Broader T Cell Responses. <i>PLoS ONE</i> , 2012, 7, e48038.	2.5	5
30	The role of small molecules in cell and gene therapy. <i>RSC Medicinal Chemistry</i> , 2021, 12, 330-352.	3.9	3
31	Success Stories and Challenges Ahead in Hematopoietic Stem Cell Gene Therapy: Hemoglobinopathies as Disease Models. <i>Human Gene Therapy</i> , 2021, 32, 1120-1137.	2.7	3
32	Gene therapy for atherosclerosis: A comparative study of adeno-associated virus (AAV) and conventional plasmid vectors encoding human apolipoprotein E (apoE) cDNAs. <i>Atherosclerosis</i> , 1999, 144, 93-94.	0.8	1
33	907. Development of Recombinant Novel Adeno-Associated Viral (rAAV) Vectors Encoding Optimised Microdystrophin cDNAs for Duchenne Muscular Dystrophy (DMD). <i>Molecular Therapy</i> , 2006, 13, S349-S350.	8.2	0
34	A Tribute to George Stamatoyannopoulos. <i>Human Gene Therapy</i> , 2016, 27, 280-286.	2.7	0